Obagi Medical Presents Pivotal Hyaluronic Acid Filler Data at ASDS Meeting, Demonstrating Non-Inferiority to Juvederm Voluma
Key Insights
Obagi Medical (search) presented pivotal clinical data at the 2025 American Society for Dermatologic Surgery Annual Meeting, with their hyaluronic acid filler study selected as a top 10 abstract for oral presentation.
The randomized, multicenter trial demonstrated non-inferiority of Obagi saypha ChIQ (search) compared to Juvederm Voluma XC (search) for midface volume restoration and nasolabial fold improvement.
Additional data included interim three-month results for Nu-Cil BioStim Scalp Serum (search) showing improvements in scalp health and hair appearance.
Obagi Medical (search) announced significant clinical data presentations at the 2025 American Society for Dermatologic Surgery (ASDS) Annual Meeting, held November 13-16, 2025, in Chicago, Illinois. The company's pivotal study comparing hyaluronic acid fillers was recognized as one of the top 10 abstracts and selected for oral presentation.
Pivotal Hyaluronic Acid Filler Study Results
The pivotal, randomized, multicenter trial compared the effectiveness and safety of two hyaluronic acid fillers for midface volume restoration and nasolabial fold improvement. The study demonstrated non-inferiority of Obagi saypha ChIQ (search) compared to Juvederm Voluma XC (search), with high patient satisfaction and robust safety across diverse skin types.
"As an investigator in this pivotal study, I was pleased that the data was recognized as one of the top 10 abstracts and selected for an oral presentation," commented Dr. Sue Ellen Cox. "The data highlights the compelling results of the Obagi saypha ChIQ (search) pivotal study and shows the potential of the product to provide high-level satisfaction for patients seeking long-lasting, natural-looking results."
Technology and Product Development
Obagi saypha ChIQ (search), developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology that creates a stable 3D HA matrix designed to provide natural-looking results with category-leading capabilities. These capabilities include high HA content upon injection, consistent gel distribution, and a predictable injection force and swelling profile. The product is currently under review for FDA approval, while Obagi Medical (search)'s saypha MagIQ was recently FDA approved.
Additional Clinical Data Presentations
The company also presented interim data from the ongoing study of Obagi Nu-Cil BioStim Scalp Serum (search), highlighting improvements in scalp health and hair appearance at three months. The serum utilizes the BioStim Complex, which employs proprietary technology powered by a synergistic blend of clinically proven actives, including biotin, amino acids, and peptides, alongside 18 essential nutrients, B vitamins, and phytoactives.
A third presentation introduced a novel scientific framework for evaluating HA fillers and showcased category-leading capabilities of the Obagi line of injectables.
Market Position and Strategic Impact
"Obagi Medical (search)'s commitment to advancing dermatologic science and driving innovation is reflected in the data shared across our skincare and injectable portfolio at the recent ASDS meeting," said Drew Fine, U.S. General Manager, Professional Channel. "New products with proven quality, a well-established safety profile, and high patient satisfaction are critical to expanding the aesthetic injectable market."
The company leverages 35 years of skin health expertise and leadership in medical-grade innovation. Obagi Medical (search) was recognized as the fastest-growing professional skincare brand in the U.S. in 2024 among the top 10 professional skin care brands, according to Kline's 2024 Global Professional Skin Care Series.